Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review0284 has been discontinued.
View all Glutamate (Metabotropic) Group I Receptors products.(1S,3R)-ACPD is an active isomer of (±)-trans-ACPD. Agonist at both group I and II mGlu receptors (EC50 values are 5, 15, 42 and 60 μM at mGluR2, mGluR5, mGluR1 and mGluR6 respectively).
NPEC-caged-(1S,3R)-ACPD, (±)-trans-ACPD and cis-ACPD also available.
分子量 | 173.17 |
公式 | C7H11NO4 |
储存 | Store at RT |
纯度 | ≥98% (HPLC) |
CAS Number | 111900-32-4 |
PubChem ID | 104766 |
InChI Key | YFYNOWXBIBKGHB-FBCQKBJTSA-N |
Smiles | N[C@]1([C@@](O)=O)C[C@]([H])([C@](O)=O)CC1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Conti et al (2002) Synthesis and pharmacology of 3-hydroxy-Δ2-isoxazoline-cyclopentance analogues of glutamic acid. Farmaco 57 889 PMID: 12484537
Knopfel et al (1995) Metabotropic glutamate receptors: novel targets for drug development. J.Med.Chem. 38 1417 PMID: 7738999
Mistry and Challis (1996) Differences in agonist and antagonist activities for two indicies of metabotropic glutamate receptor-stimulated phosphoinositide turnover. Br.J.Pharmacol. 117 1735 PMID: 8732284
关键词: (1S,3R)-ACPD, (1S,3R)-ACPD supplier, Group, II, group, I, mGlur, agonists, Receptors, mGlu2, mGlu3, mGluR2, mGluR3, Glutamate, Metabotropic, mGlu1, mGlu5, mGluR1, mGluR5, (Metabotropic), 0284, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 (1S,3R)-ACPD 的部分引用包括:
Tang et al (2015) Stimulation-evoked Ca2+ signals in astrocytic processes at hippocampal CA3-CA1 synapses of adult mice are modulated by glutamate and ATP. J Neurosci 35 3016 PMID: 25698739
Yamada et al (2008) Long-range axonal calcium sweep induces axon retraction. Sci Adv 28 4613 PMID: 18448637
Scholler (2017) HTS-compatible FRET-based conformational sensors clarify membrane receptor activation. Nat Chem Biol 13 372 PMID: 28135236
Andlauer et al (2014) Drep-2 is a novel synaptic protein important for learning and memory. J Neurosci 3 PMID: 25392983
Pasquale and Sherman (2013) A modulatory effect of the feedback from higher visual areas to V1 in the mouse. J Neurophysiol 109 2618 PMID: 23446698
Blanco et al (2008) Tone-dependent vascular responses to astrocyte-derived signals. Am J Physiol Heart Circ Physiol 294 H2855 PMID: 18456724
目前没有该产品的评论。 Be the first to review (1S,3R)-ACPD and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.